(News Bulletin 247) – The American-Swiss biotechnology company Sophia Genetics announced on Monday that it will strengthen its collaboration with AstraZeneca in order to apply its multimodal analysis capabilities to the pharmaceutical group’s oncology drug projects.
The approach will consist of combining data generated through the analysis of radiological images, molecular diagnostics, clinical data from other pathological fields with artificial intelligence and machine learning technologies.
The two partners intend in particular to be able to accelerate clinical studies, generate evidence of clinical efficacy with a view to regulatory approvals and facilitate decision support so that doctors can choose the treatment best suited to their patients. .
Based between Boston and Lausanne, Sophia Genetics is at the origin of a ‘cloud’ platform capable of analyzing data from complex multimodal datasets and different diagnostic modes.
Its products and services are currently used by many hospitals, laboratories and biopharmaceutical establishments around the world.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
